Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer

Am J Pathol. 2005 Apr;166(4):1229-38. doi: 10.1016/S0002-9440(10)62341-3.

Abstract

Invasive cervical carcinomas almost invariably carry extra copies of chromosome arm 3q, resulting in a gain of the human telomerase gene (TERC). This provided the rationale for the development of a multicolor fluorescence in situ hybridization (FISH) probe set as a diagnostic tool for the direct detection of TERC gains in Pap smears. We previously used this probe set to show that cervical intraepithelial neoplasia (CIN) 2 and CIN3 lesions could be distinguished from normal samples, atypical squamous cell of undetermined significance (ASCUS) and CIN1, with a sensitivity and specificity exceeding 90%, independent of the cytomorphological assessment. In the current study, we explored whether gain of 3q and amplification of TERC could predict progression from CIN1/CIN2 to CIN3 and invasive carcinoma. We applied our probe set to a series of 59 previously stained Pap smears for which repeat Pap smears and clinical follow-up were available. The samples included CIN1/CIN2 lesions that progressed to CIN3 (progressors), CIN1/CIN2 lesions that regressed spontaneously (regressors), and normal Pap smears from women who subsequently developed CIN3 or cervical cancer. Here, we show that progressors displayed a gain of 3q whereas none of the regressors showed this genetic aberration. These data suggest that 3q gain is required for the transition from CIN1/CIN2 to CIN3 and that it predicts progression. Of note, 3q gain was found in 33% of cytologically normal Pap smears from women who were diagnosed with CIN3 or invasive cervical carcinoma after a short latency. The sensitivity of our test for predicting progression from CIN1/CIN2 to CIN3 was 100% and the specificity, ie, the prediction of regression, was 70%. We conclude that the detection of 3q gain and amplification of TERC in routinely collected Pap smears can assist in identifying low-grade lesions with a high progression risk and in decreasing false-negative cytological screenings.

MeSH terms

  • Adult
  • Biomarkers, Tumor / analysis*
  • Disease Progression
  • Female
  • Humans
  • In Situ Hybridization, Fluorescence
  • Middle Aged
  • Papanicolaou Test
  • RNA / genetics*
  • Retrospective Studies
  • Sensitivity and Specificity
  • Telomerase / genetics*
  • Uterine Cervical Dysplasia / genetics*
  • Uterine Cervical Dysplasia / pathology*
  • Uterine Cervical Neoplasms / genetics*
  • Uterine Cervical Neoplasms / pathology*
  • Vaginal Smears

Substances

  • Biomarkers, Tumor
  • telomerase RNA
  • RNA
  • Telomerase